Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $223000.0.

  • Insight Molecular Diagnostics' Non Operating Income rose 32075.47% to $223000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $651000.0, marking a year-over-year increase of 1128.21%. This contributed to the annual value of $462000.0 for FY2024, which is 1725.89% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Non Operating Income is $223000.0, which was up 32075.47% from $125000.0 recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Non Operating Income peaked at $1.3 million during Q2 2021, and registered a low of -$919000.0 during Q4 2022.
  • Its 5-year average for Non Operating Income is $59894.7, with a median of $110000.0 in 2024.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Non Operating Income soared by 47676.47% in 2021, and later tumbled by 75092.59% in 2022.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Non Operating Income stood at -$108000.0 in 2021, then plummeted by 750.93% to -$919000.0 in 2022, then skyrocketed by 129.27% to $269000.0 in 2023, then plummeted by 45.72% to $146000.0 in 2024, then skyrocketed by 52.74% to $223000.0 in 2025.
  • Its Non Operating Income was $223000.0 in Q3 2025, compared to $125000.0 in Q2 2025 and $157000.0 in Q1 2025.